ArticleMolecular & cellular proteomics : MCP2015
Towards High-throughput Immunomics for Infectious Diseases: Use of Next-generation Peptide Microarrays for Rapid Discovery and Mapping of Antigenic Determinants.
Article in Molecular & cellular proteomics : MCP, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 86 citations in OpenAlex.
- Reconstructing pathogen-specific antibody binding epitopes and age-dependent immune signatures from proteomic-scale peptide libraries.Science advances · 2026Article
- Conjugates of α-d-Galp-(1→3)-β-d-Galp for the serological diagnosis of Chagas disease.PLoS neglected tropical diseases · 2026Article
- Software and Tools to Analyze High-Density Peptide Array Data for the Chagas Antigen and Epitope Atlas.Methods in molecular biology (Clifton, N.J.) · 2026Article
- B-EPIC: A Transformer-Based Language Model for Decoding B Cell Immunodominance Patterns.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Identification of highly conservedEmerging microbes & infections · 2024Article
- Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review.Lancet regional health. Americas · 2024Review
- BacScan: a novel genome-wide strategy for uncovering broadly immunogenic proteins in bacteria.Frontiers in immunology · 2024Article
- Deep serological profiling of the Trypanosoma cruzi TSSA antigen reveals different epitopes and modes of recognition by Chagas disease patients.PLoS neglected tropical diseases · 2023Article
- The Trypanosoma cruzi Antigen and Epitope Atlas: antibody specificities in Chagas disease patients across the Americas.Nature communications · 2023Article
- Virome-wide detection of natural infection events and the associated antibody dynamics using longitudinal highly-multiplexed serology.Nature communications · 2023Article
- A novel precision-serology assay for SARS-CoV-2 infection based on linear B-cell epitopes of Spike protein.Frontiers in immunology · 2023Article
- Challenges in Serologic Diagnostics of Neglected Human Systemic Mycoses: An Overview on Characterization of New Targets.Pathogens (Basel, Switzerland) · 2022Review
- Autoimmunity to the Follicle-Stimulating Hormone Receptor (FSHR) and Luteinizing Hormone Receptor (LHR) in Polycystic Ovarian Syndrome.International journal of molecular sciences · 2021Article
- A refined genome phage display methodology delineates the human antibody response in patients with Chagas disease.iScience · 2021Article
- Identification of antigenic linear peptides in the soil-transmitted helminth and Schistosoma mansoni proteome.PLoS neglected tropical diseases · 2021Article
- Serological Approaches for Trypanosoma cruzi Strain Typing.Trends in parasitology · 2021Review
- AssessingPathogens (Basel, Switzerland) · 2021Article
- SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region.Vaccines · 2021Article
- APRANK: Computational Prioritization of Antigenic Proteins and Peptides From Complete Pathogen Proteomes.Frontiers in immunology · 2021Article
- Rapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays.Journal of proteome research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complete characterization of antibody specificities associated to natural infections is expected to provide a rich source of serologic biomarkers with potential applications in molecular diagnosis, follow-up of chemotherapeutic treatments, and prioritization of targets for vaccine development. Here, we developed a highly-multiplexed platform based on next-generation high-density peptide microarrays to map these specificities in Chagas Disease, an exemplar of a human infectious disease caused by the protozoan Trypanosoma cruzi. We designed a high-density peptide microarray containing more than 175,000 overlapping 15 mer peptides derived from T. cruzi proteins. Peptides were synthesized in situ on microarray slides, spanning the complete length of 457 parasite proteins with fully overlapped 15 mers (1 residue shift). Screening of these slides with antibodies purified from infected patients and healthy donors demonstrated both a high technical reproducibility as well as epitope mapping consistency when compared with earlier low-throughput technologies. Using a conservative signal threshold to classify positive (reactive) peptides we identified 2,031 disease-specific peptides and 97 novel parasite antigens, effectively doubling the number of known antigens and providing a 10-fold increase in the number of fine mapped antigenic determinants for this disease. Finally, further analysis of the chip data showed that optimizing the amount of sequence overlap of displayed peptides can increase the protein space covered in a single chip by at least ∼ threefold without sacrificing sensitivity. In conclusion, we show the power of high-density peptide chips for the discovery of pathogen-specific linear B-cell epitopes from clinical samples, thus setting the stage for high-throughput biomarker discovery screenings and proteome-wide studies of immune responses against pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.